[{"orgOrder":0,"company":"Molteni Farmaceutici","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Peptide","year":"2020","type":"Public Offering","leadProduct":"JT-09","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Molteni Farmaceutici","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Molteni Farmaceutici \/ Titan Pharmaceuticals Inc","highestDevelopmentStatusID":"4","companyTruncated":"Molteni Farmaceutici \/ Titan Pharmaceuticals Inc"},{"orgOrder":0,"company":"Molteni Farmaceutici","sponsor":"Accord healthcare","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Molteni Farmaceutici","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"Molteni Farmaceutici \/ Molteni Farmaceutici","highestDevelopmentStatusID":"15","companyTruncated":"Molteni Farmaceutici \/ Molteni Farmaceutici"}]

Find Clinical Drug Pipeline Developments & Deals by Molteni Farmaceutici

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Under the terms of the agreement, Accord will commercialize Sixmo®▼ (buprenorphine implant), an opioid agonist therapy treatment, delivered through a first-of-its-kind implant, placed under the skin for six-months.

                          Product Name : Sixmo

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          September 14, 2020

                          Lead Product(s) : Buprenorphine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Recipient : Accord healthcare

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : As a result of the debt settlement with Molteni and Horizon, there are no liens remaining on any of Titan's assets. With the net proceeds from recent public the company is well positioned to progress preclinical development of its ProNeura-based pipeline...

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          February 11, 2020

                          Lead Product(s) : JT-09

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Sponsor : Titan Pharmaceuticals Inc

                          Deal Size : Undisclosed

                          Deal Type : Public Offering

                          blank

                          03

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          November 11, 2013

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Mario Negri Sud

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank